Work

Study on the application of pelvic bone marrow-sparing volumetric modulated arc therapy in concurrent chemoradiotherapy for cervical cancer patients

Year: 2026
Type: article
Abstract: This study investigated the dosimetric, hematologic toxicity (HT), and clinical efficacy benefits of pelvic bone marrow-sparing volumetric modulated arc therapy (PBMS-VMAT) in cervical cancer patients undergoing concurrent chemoradiotherapy (CCRT). Between October 2023 and March 2024, 244 cervical cancer patients undergoing CCRT were enrolled and classified into the PBMS-VMAT group or the control group. The PBMS-VMAT group received additional pelvic bone marrow (BM) dose-volume constraints. Dosimetric parameters, acute HT, and preliminary clinical efficacy were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for grade 2 or higher (G2 + ) HT. Dynamic changes in lymphocyte counts were also evaluated. There were no statistically significant differences in target-volume dosimetric parameters between the two groups. However, PBMS-VMAT significantly reduced pelvic BM V 10 , V 20 , and V 40 values, while no significant differences were observed in bladder, rectum, bowel, or femoral head dosimetry. G2 + HT was significantly lower in the PBMS-VMAT group (51.6% vs. 73.0%; 95% CI : − 37.8% to − 4.0%; P = 0.014), and lymphocyte counts were higher during and after CCRT. The complete response rate was 61.48% in the PBMS-VMAT group versus 48.36% in the control group (95% CI : 0.86%–24.38%; P = 0.04). Among all variables examined, V 10 remained the only factor independently associated with HT (odds ratio 1.16; 95% CI : 1.07–1.26; P < 0.001). PBMS-VMAT not only limits acute radiation-induced lymphopenia but also shortens the recovery window. In cervical cancer patients undergoing CCRT, PBMS-VMAT effectively protects bone marrow hematopoietic function while maintaining target dose coverage and satisfying organ-at-risk dose constraints. Thus, PBMS-VMAT may represent a superior radiotherapy technique for CCRT in cervical cancer and holds promise for broader clinical application.
Language: English
Subfield: Radiation
Open Access status: gold
Estimated APC paid: $4,390
OpenAlex ID: W7229603452
FWCI:
Cites:
Cited by:
Related to: 10